Protein Degradation and Inhibitors

SEP 8, 2026 · JOURNAL ARTICLE

Targeted protein degradation dismantles undruggable targets to reverse immune evasion and therapy resistance in cancer

Frontiers in Immunology

A comprehensive review summarizing molecular principles, clinical progress, and translational strategies for targeted protein degradation in cancer immunotherapy, rather than reporting original experimental data or trial results.

SEP 8, 2026 · JOURNAL ARTICLE

An AI-Assisted Workflow for Rapid Prioritization of FDA-Approved Drugs as HDAC3 Inhibitor Candidates for Drug Repurposing

Biology

This is an exploratory computational study using machine learning to predict HDAC3 inhibition by FDA-approved drugs, without experimental validation or clinical data, raising mechanistic questions rather than answering therapeutic ones.

SEP 8, 2026 · JOURNAL ARTICLE

Translational advances in p53 targeted cancer therapy from molecular mechanisms to clinical application

Discover Oncology

A narrative review evaluating translational barriers to p53-targeted therapy, raising mechanistic questions and proposing future directions rather than reporting a new trial result or establishing clinical efficacy.

SEP 8, 2026 · JOURNAL ARTICLE

Targeting LZK in Oral Squamous Cell Carcinoma: A Review of Local PROTAC Delivery via Dissolving Microneedles

Theoretical and Natural Science

This is a narrative review proposing a theoretical therapeutic strategy combining LZK-PROTAC degradation with dissolving microneedle delivery for OSCC; no clinical trial data, preclinical evidence, or mechanistic validation is presented.

SEP 7, 2026 · JOURNAL ARTICLE

Molecular Glue Degraders in Early Development for Cancer Therapy

Medicinal Research Reviews

This is a mechanistic review of an emerging drug class with no clinical efficacy data, preclinical results, or trial outcomes reported; it raises scientific questions about molecular glue degraders rather than answering them with evidence.

SEP 4, 2026 · JOURNAL ARTICLE

Structure-based discovery of coumarin-derived HDAC2 inhibitor through integrated computational bioassays, steered molecular dynamics, network analysis and SAR

Main Group Chemistry

Structure-based computational discovery of a novel HDAC2 inhibitor with predicted superior binding and activity; lacks experimental validation in cells or organisms, representing early-stage hypothesis-generating work.

AUG 18, 2026 · JOURNAL ARTICLE

Optimizationof a Series of Novel 1 H -Pyrrolo[3,2- c ]pyridine-Based USP1Inhibitors with Potent In Vivo Antitumor Activity

Journal of Medicinal Chemistry

Early-stage preclinical chemistry and pharmacology study demonstrating lead compound design and in vivo efficacy in xenograft models, without clinical trial data or regulatory approval.

AUG 17, 2026 · JOURNAL ARTICLE

Pamiparib plus surufatinib with ctDNA monitoring in platinum-resistant ovarian cancer after PARP inhibitor progression: a phase Ib/II trial (POST-PARPi)

BMC Medicine

Phase Ib/II trial showing modest efficacy (46.7% 6-month PFS) with manageable toxicity in a treatment-refractory population, but limited by small sample size, low objective response rate, and single-arm design without comparator.